Related Experiment Video
Updated: May 21, 2026

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
Caspase inhibitors: prospective therapies for stroke
1Department of Department of Pathology & Cell Biology, Columbia University, New York, NY 10032, USA. nea2107@columbia.edu
Abstract:
In ischemic stroke, apoptosis persists for days to weeks after the onset of an ischemic event. Cysteine-ASPartic proteASEs (caspases) are key mediators of apoptosis and neurodegeneration in stroke. The impact of caspase activity is not restricted to neuronal death, as caspases can exacerbate inflammation and alter glial function. Thus, caspases are logical therapeutic targets for this disease, but they have never been clinically evaluated due to a paucity of ideal drug candidates. Recent developments in caspase inhibition and drug delivery offer novel neuroprotective strategies for stroke, which are deliberated in this review.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

